ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

Core Viewpoint - ADMA Biologics, Inc. will report its fourth quarter and full year 2025 financial results on February 25, 2026, followed by a conference call to discuss these results and company updates [1]. Group 1: Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM, and NABI-HB, aimed at treating immune deficiencies and preventing certain infectious diseases [3]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia [3]. - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [3]. - ADMA holds numerous U.S. and foreign patents related to its products and candidates [3].